- Home
- SLN vs MBCN Comparison
SLN vs MBCN Comparison
Compare SLN & MBCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | MBCN |
|---|---|---|
| Founded | 1994 | 1901 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 274.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLN | MBCN |
|---|---|---|
| Price | $6.57 | $37.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $39.67 | $35.00 |
| AVG Volume (30 Days) | ★ 314.1K | 16.6K |
| Earning Date | 11-06-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | N/A | ★ 48.42 |
| EPS | N/A | ★ 2.61 |
| Revenue | $25,830,000.00 | ★ $75,400,000.00 |
| Revenue This Year | N/A | $19.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | ★ N/A | $14.13 |
| Revenue Growth | ★ 40.39 | 16.60 |
| 52 Week Low | $1.97 | $22.74 |
| 52 Week High | $8.08 | $37.68 |
Technical Indicators
Market Signals| Indicator | SLN | MBCN |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 66.64 |
| Support Level | $5.95 | $36.84 |
| Resistance Level | $6.60 | $37.68 |
| Average True Range (ATR) | 0.53 | 0.79 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 41.33 | 82.90 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About MBCN Middlefield Banc Corp.
Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.